The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 06, 2018

Filed:

Sep. 14, 2015
Applicant:

The Board of Trustees of the University of Illinois, Urbana, IL (US);

Inventors:

Tapas Das Gupta, River Forest, IL (US);

Ananda Chakrabarty, Villa Park, IL (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/16 (2006.01); C07K 14/195 (2006.01); C07K 14/21 (2006.01); C07K 14/35 (2006.01); C07K 14/415 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); C07K 14/22 (2006.01); C07K 14/225 (2006.01); C07K 14/235 (2006.01); C07K 14/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/16 (2013.01); A61K 38/164 (2013.01); A61K 38/168 (2013.01); A61K 45/06 (2013.01); C07K 14/195 (2013.01); C07K 14/21 (2013.01); C07K 14/22 (2013.01); C07K 14/225 (2013.01); C07K 14/235 (2013.01); C07K 14/28 (2013.01); C07K 14/35 (2013.01); C07K 14/415 (2013.01); G01N 33/5011 (2013.01); G01N 33/5017 (2013.01); G01N 33/569 (2013.01); A61K 38/00 (2013.01); G01N 2510/00 (2013.01);
Abstract

The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.


Find Patent Forward Citations

Loading…